Last update :
22/04/2025
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
valistab
valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Antimuscarinic   Glycopyrronium bromide  
injection
Oral solution
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Glycopyrronium Denmark, Finland, Germany, Great Britain, Ireland, Norway, Sweden
Robinul Austria, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Slovenia, Sweden, Switzerland, United States of America
Stability of mixtures   injection   Stability of mixtures : Glycopyrronium bromide     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass None 0,1 mg/ml
injection   Glycopyrronium bromide   
injection   Palonosetron hydrochloride 25 µg/ml
25°C
4 Hour
Not specified 2286
Level of evidence A+
Polyvinyl chloride Sodium chloride 0,9% 15 mg/ml
injection   Glycopyrronium bromide   
injection   Haloperidol lactate 52 mg/ml
injection   Buprenorphine hydrochloride 57 mg/ml
21°C
30 Day
Protect from light 2113
Level of evidence D
Polyvinyl chloride Sodium chloride 0,9% 15 mg/ml
injection   Glycopyrronium bromide   
injection   Haloperidol lactate 52 mg/ml
injection   Buprenorphine hydrochloride 57 mg/ml
36°C
9 Day
Protect from light 2113
Level of evidence D
Polyvinyl chloride Sodium chloride 0,9% 15 mg/ml
injection   Glycopyrronium bromide   
injection   Haloperidol lactate 52 mg/ml
injection   Buprenorphine hydrochloride 57 mg/ml
4°C
30 Day
Protect from light 2113
Level of evidence D
Polypropylene Sodium chloride 0,9% 15 mg/ml
injection   Glycopyrronium bromide   
injection   Haloperidol lactate 52 mg/ml
injection   Buprenorphine hydrochloride 57 mg/ml
21°C
30 Day
Protect from light 2113
Level of evidence D
Polypropylene Sodium chloride 0,9% 0,1 mg/ml
injection   Glycopyrronium bromide   
injection   Ondansetron hydrochloride 1 mg/ml
23°C
24 Hour
Light 815
Level of evidence C+
Polypropylene Sodium chloride 0,9% 15 mg/ml
injection   Glycopyrronium bromide   
injection   Haloperidol lactate 52 mg/ml
injection   Buprenorphine hydrochloride 57 mg/ml
36°C
16 Day
Protect from light 2113
Level of evidence D
Polypropylene Sodium chloride 0,9% 15 mg/ml
injection   Glycopyrronium bromide   
injection   Haloperidol lactate 52 mg/ml
injection   Buprenorphine hydrochloride 57 mg/ml
4°C
30 Day
Protect from light 2113
Level of evidence D
Polypropylene Sodium chloride 0,9% 0,1 mg/ml
injection   Glycopyrronium bromide   
injection   Ondansetron hydrochloride 1 mg/ml
4°C
24 Hour
Protect from light 815
Level of evidence C+
  Mentions Légales